Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.

NCT03981900 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03981900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03981900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 4, 2019
Completion date
February 6, 2023
Enrollment
314 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid